Henrich, co-authors find no advantage to renal-artery stents

Posted: Tuesday, November 26, 2013

The study co-authored by William L. Henrich, M.D., MACP, president of the UT Health Science Center San Antonio, found that adding renal-artery stents to therapy did not reduce the risk of heart attack, stroke or kidney failure.

clear graphic
The study co-authored by William L. Henrich, M.D., MACP, president of the UT Health Science Center San Antonio, found that adding renal-artery stents to therapy did not reduce the risk of heart attack, stroke or kidney failure.  

Email Printer Friendly Format
 

Contact: Will Sansom, 210-567-2579

SAN ANTONIO (Nov. 19, 2013) — William L. Henrich, M.D., MACP, a renal specialist who is president of The University of Texas Health Science Center at San Antonio, co-authored a multicenter research study published earlier this month in The New England Journal of Medicine.

The CORAL (Cardiovascular Outcomes in Renal Atherosclerotic Lesions) trial compared cardiovascular and renal outcomes of elderly patients presenting with renal-artery stenosis (a constriction of the artery in the kidney) and hypertension or chronic kidney disease. One group was treated with renal-artery stenting and medicine while a second group was treated with medicine alone.

Stents brought no significant improvement
Although a modest decrease in systolic blood pressure was noted in the stent-treated patients, the CORAL investigators found no difference between the groups in the occurrence of cardiovascular and renal events such as heart attack, stroke, hospitalization for congestive heart failure and progressive renal insufficiency. Patient follow-up averaged three and a half years.

“The renal arteries, which carry blood to the kidneys, become occluded (blocked) in an estimated 1 percent to 5 percent of elderly patients with arterial disease,” Dr. Henrich said. “This contributes to hypertension, ischemic nephropathy resulting in kidney cell death, and other long-term complications. Stents may be placed to restore circulation in these arteries. Our study evaluated whether stents, when added to medical therapy, decreased the occurrence of adverse events. Our findings showed this is not the case.”

The CORAL study enrolled more than 900 participants from medical centers including the UT Health Science Center, where Dr. Henrich is a nephrologist with UT Medicine San Antonio, the clinical practice of the School of Medicine. Lead author of the paper is Christopher J. Cooper, M.D., of the University of Toledo.

According to the CORAL investigators, renal-artery stenting for Medicare beneficiaries grew rapidly in the 1990s, with annual procedure volumes increasing 364 percent between 1996 and 2000. However, three randomized trials of renal-artery angioplasty failed to demonstrate a blood pressure benefit. No previous trial had as its primary endpoint adverse clinical events.

# # #

UT Medicine San Antonio is the clinical practice of the School of Medicine at the UT Health Science Center San Antonio. With more than 700 doctors – all School of Medicine faculty members – UT Medicine is the largest medical practice in Central and South Texas. Expertise is in more than 100 medical specialties and subspecialties. Primary care doctors and specialists see patients in private practice at UT Medicine’s flagship clinical home, the Medical Arts & Research Center (MARC), located at 8300 Floyd Curl Drive, San Antonio 78229. Most major health plans are accepted, and UT Medicine physicians also practice at several local and regional hospitals. Call 210-450-9000 to schedule an appointment, or visit www.UTMedicine.org for a list of clinics and phone numbers.



HOME [HSC NEWS] | About UTHSCSA | News Releases | Mission Magazine | Grand Rounds Newly Granted | Submit News | HSC News Archive | Video Index
Photo Archive Library News | Update(Student Newsletter) | RAHC